Semaglutide 7.2mg: separating the facts from the hype

The myth worth correcting first: 7.2mg is not a shortcut to faster results

A lot of the online conversation around semaglutide 7.2mg reads as though reaching this dose is the point of treatment — a finish line to sprint towards. That picture is wrong in two important ways. First, the titration schedule exists for a reason. The GI side effects that most people notice on semaglutide (nausea, loose stools, reflux) are closely linked to how quickly the dose climbs, so reaching 7.2mg before your system has adjusted is more likely to mean more weeks of feeling unwell than it is to mean faster weight loss. Second, many people find that they reach a maintenance dose well below 7.2mg that works effectively for them, and their prescriber may never recommend going higher. The higher ceiling is genuinely useful for people who have plateaued on lower doses and tolerated them well. It is not a default destination.

The MHRA's approval of the dedicated single-dose 7.2mg pen in April 2026 was significant because it simplifies the administration: one pen, one injection per week, rather than the earlier arrangement of three separate 2.4mg pens. For anyone who found the previous multi-pen format complicated, that is a practical improvement worth knowing about. You can read more about how the different Wegovy doses fit together on our guide to Wegovy doses.

What the trial evidence actually says about 7.2mg semaglutide

The figure of approximately 20.7% average weight loss at 72 weeks comes from trial data submitted to the MHRA as part of the approval process for the 7.2mg dose. For context, the pivotal STEP 1 trial (which formed the basis of Wegovy's original UK licence) reported around 15% average body-weight reduction at 68 weeks with the 2.4mg dose, as published in the New England Journal of Medicine. The jump to roughly 20% with 7.2mg is meaningful, and it matters for the broader comparison: tirzepatide (Mounjaro) produced average reductions of around 20–21% in its SURMOUNT-1 trial. Semaglutide at 7.2mg narrows that gap considerably.

That said, averages are averages. Individual responses to any GLP-1 medicine vary quite widely, and a person who responded well to 2.4mg semaglutide may not see meaningfully more weight loss at 7.2mg. A person who struggled to tolerate lower doses may find the titration to 7.2mg difficult to complete. Neither outcome is a failure, it reflects how variable human biology is.

If you are weighing up semaglutide against tirzepatide, our Wegovy overview covers how both medicines sit within the licensed UK landscape, including the head-to-head SURMOUNT-5 evidence.

Who can actually access semaglutide 7.2mg in the UK right now

The 7.2mg pen carries the same core licensing criteria as earlier Wegovy doses for weight management: adults with a BMI of 30 or above, or 27 to 29.9 with at least one weight-related health condition such as high blood pressure, high cholesterol or type 2 diabetes. The one restriction specific to this dose is that the cardiovascular risk-reduction indication (which Wegovy also holds) is not included; the 7.2mg pen is licensed for weight management only.

It is also worth understanding that arriving at 7.2mg as your maintenance dose is a clinical decision made during treatment, not something that is fixed at the start. Prescribers follow the titration schedule and assess tolerance at each step. You would not be prescribed 7.2mg as a starting point. If you are curious about where the titration begins, our page on the semaglutide dose schedule explains the full sequence, and our 1mg semaglutide page covers one of the earlier steps in more detail. For those approaching the upper end of the schedule, our page on 3mg semaglutide covers the step that typically precedes the move to higher doses.

On the NHS, access to semaglutide remains through specialist weight management services under NICE guidance TA875, and waiting lists are commonly long. For many people, a private route through a regulated online pharmacy is the practical alternative while NHS capacity grows. If you want to understand the cost side of private treatment, our treatment page sets out what is included in the price. We are honest that we are not positioned as the cheapest option, because a single transparent price that covers clinical assessment, prescription and aftercare is a different thing from a low headline figure.

Side effects to be aware of at higher semaglutide doses

If you are already on semaglutide and your prescriber is discussing moving toward 7.2mg, it is natural to wonder whether side effects get worse at the higher dose. Generally, GI effects (nausea, vomiting, diarrhoea, constipation, reflux) are most noticeable after each dose increase, then tend to settle over a week or two as the body adjusts. That pattern tends to continue with each step up the schedule, which is one reason the titration is gradual.

In January 2026 the MHRA issued a Drug Safety Update specifically highlighting acute pancreatitis as a known infrequent but serious side effect of GLP-1 medicines. Severe stomach pain that radiates toward the back, with or without vomiting, is a symptom that needs urgent medical attention rather than waiting to see if it settles. The NHS semaglutide page lists the full side-effect profile and the signs that should prompt a call to 111 or a GP. You can also report any suspected side effects through the MHRA's Yellow Card scheme, which helps regulators track safety signals across the population.

If you have questions about your current treatment or are considering moving to a higher dose, speaking to a prescriber is the right first step. Dose decisions should not be based on online reading alone. When you are ready, you are welcome to speak to our prescribers at nume, who review every consultation personally on the same day it is submitted.